How U.S. Pandemic Vaccine Funding Cuts Could Affect Medicare Costs

When most Medicare beneficiaries think about their health coverage, they think about premiums, copays, and whether their doctor is in-network. Few think about a Norway-based vaccine coalition called CEPI — the Coalition for Epidemic Preparedness Innovations. But the Trump administration's decision to freeze and ultimately disrupt U.S. financial support for CEPI may matter more to seniors on Medicare than it first appears. Here's why: the vaccines CEPI is developing today are the ones Medicare would be covering — and paying for — during the next pandemic or epidemic outbreak. And if that pipeline slows down, the downstream costs and coverage gaps for Medicare beneficiaries could be significant.

CEPI was founded in 2017 with a specific mission: accelerate the development of vaccines and medical countermeasures against high-threat pathogens before they become global emergencies. It pools contributions from more than 30 governments, philanthropic foundations, and private sector partners to fund research into diseases that the private market alone would never prioritize — because the commercial return is too uncertain. Lassa fever, MERS, Nipah virus, Rift Valley fever — these are not household names, but they are diseases that infectious disease specialists have flagged as having serious pandemic potential. CEPI is currently running clinical trials on vaccine candidates for all four of them. It also contributed to the development of seven COVID-19 vaccines that received regulatory approval globally, and it helped bring the first-ever licensed Chikungunya vaccine to market.

The United States made its first financial contribution to CEPI in 2020, and through August 2026 has invested a total of $217 million in the organization. That funding came through multiple channels — not just direct appropriations, but also through partnerships with the U.S. International Development Finance Corporation, the Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA). These weren't charity donations. They were strategic investments in the kind of early-stage vaccine research that protects Americans — including the 67 million people enrolled in Medicare — from the next COVID-level health and economic disruption.

Starting on the first day of his second term, President Trump issued executive actions that fundamentally restructured U.S. foreign assistance. A 90-day review of all foreign aid was ordered, followed by a stop-work order that froze payments and services for programs already underway. USAID was effectively dissolved, with most staff and contractors reduced or eliminated. Most foreign assistance awards were cancelled outright. A humanitarian waiver was issued, but it was narrow in scope and difficult for program implementers to actually use. Since then, responsibility for remaining global health programs has been transferred to the State Department, though the transition has been far from seamless. Legal challenges to these actions have produced limited remedy. The practical result: U.S. global health programs, including support for organizations like CEPI, were disrupted and in some cases ended entirely.

So what does this mean for a 72-year-old in Phoenix or a 68-year-old in rural Ohio who is enrolled in a Medicare Advantage plan? The connection runs through several channels. First, consider what happened during COVID-19. Medicare Part B covered FDA-authorized COVID-19 vaccines at no cost to beneficiaries — no copay, no deductible. That was possible in part because the U.S. government had invested heavily in accelerating vaccine development through programs like Operation Warp Speed, which itself drew on CEPI's research infrastructure and global laboratory networks. If the next pandemic arrives and the U.S. has weakened its investment in early-stage vaccine development, the timeline from outbreak to approved vaccine could stretch from months to years. During that gap, Medicare beneficiaries — who are statistically the most vulnerable to severe outcomes from respiratory and infectious diseases — would bear the greatest health burden.

Second, there is a direct cost question. According to CMS.gov data, Medicare Part B covered approximately 49 million beneficiaries in 2024, and vaccine-related spending under Part B has grown substantially since the COVID-19 era. The Inflation Reduction Act of 2022 made all adult vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) free under Medicare Part D starting in 2023 — no cost-sharing for beneficiaries. That was a landmark change. But it only applies to vaccines that exist and have received ACIP recommendations. If CEPI's pipeline for Nipah or Lassa fever vaccines is delayed by years due to funding disruptions, Medicare beneficiaries won't have access to those vaccines — not because of coverage rules, but because the vaccines won't exist yet when they're needed.

Third, Medicare Advantage plans — which now cover more than 54% of all Medicare beneficiaries according to CMS.gov enrollment data for 2025 — handle vaccine and preventive care benefits differently than Original Medicare. While all Medicare Advantage plans are required to cover the same vaccines as Original Medicare Part B and Part D at no cost, the administrative process varies. Some plans require you to use in-network pharmacies or providers for vaccine administration. Others have prior authorization requirements for certain biologics and newer immunizations. If a novel vaccine for a newly emerged pathogen receives emergency use authorization and Medicare moves to cover it, beneficiaries in Medicare Advantage plans may face a brief but frustrating lag while their plan updates its formulary and coverage policies. Understanding your plan's vaccine coverage process before an emergency — not during one — is the practical takeaway here.

For the 2026 plan year, the average Medicare Advantage plan premium is approximately $17 per month, according to CMS.gov data, though many plans continue to offer $0-premium options in competitive markets. The average Medicare Part D standalone plan premium in 2026 is around $46 per month, though the Inflation Reduction Act's $2,000 out-of-pocket cap on Part D drug costs — which took effect in 2025 — provides meaningful protection for beneficiaries who need expensive medications, including antivirals that might be prescribed during an outbreak. These numbers matter because they frame the financial stakes: Medicare beneficiaries are already navigating a complex cost landscape, and any future pandemic that arrives without a ready vaccine would add pressure to that system in ways that are difficult to predict but easy to imagine.

Data Snapshot: According to CMS.gov data, there were 3,959 Medicare Advantage plans available nationwide for the 2025 plan year, with an average of 43 plans per county — giving most beneficiaries a wide range of options during the Annual Enrollment Period. Of those plans, CMS reported that roughly 45% received a star rating of 4 or higher in 2025, meaning nearly half of available plans met CMS's threshold for above-average quality. Star ratings directly affect plan bonuses and, indirectly, the extra benefits plans can afford to offer — including expanded preventive care, telehealth, and wellness programs that become especially valuable during public health emergencies.

The broader policy concern for Medicare beneficiaries is this: pandemic preparedness is not an abstract foreign policy issue. It is a Medicare issue. The COVID-19 pandemic cost Medicare an estimated $50 billion in additional spending in 2020 alone, according to MedPAC analysis, as hospitalizations surged among older adults. The investments the U.S. made in organizations like CEPI were, in part, an attempt to reduce the probability and severity of that kind of shock happening again. Pulling back from those investments doesn't eliminate the risk — it just shifts the cost to a future date, when the bill will be paid in hospitalizations, ICU stays, and Medicare expenditures rather than in research grants.

If you are currently enrolled in Medicare and want to understand how your specific plan handles vaccine coverage and preventive care, the most direct step is to call your plan's member services number — it's on the back of your insurance card — and ask two specific questions: Does my plan require prior authorization for newly approved vaccines? And does my plan cover vaccine administration at any licensed pharmacy, or only in-network locations? These questions take five minutes to ask and could save you significant confusion during a future health emergency. You can also use the Medicare Plan Finder at Medicare.gov to compare plans side by side on preventive care benefits before the Annual Enrollment Period opens on October 15 and closes December 7.

For beneficiaries who are not yet in Medicare Advantage and are still in Original Medicare, vaccine coverage under Part B is straightforward: flu shots, COVID-19 vaccines, pneumococcal vaccines, and hepatitis B vaccines are covered at no cost when administered by a Medicare-enrolled provider. Part D covers all ACIP-recommended adult vaccines at no cost-sharing as of 2023. The gap to watch is for vaccines that are newly authorized during an emergency — those may take weeks to be formally added to Part D formularies, though CMS has historically moved quickly to issue guidance during public health emergencies.

The Annual Enrollment Period — October 15 through December 7 each year — is the primary window when Medicare beneficiaries can switch from Original Medicare to Medicare Advantage, change Medicare Advantage plans, or adjust their Part D drug coverage. Changes made during AEP take effect January 1. If you are concerned about how your current plan handles pandemic-related coverage, or if you want a plan with stronger preventive care benefits, AEP is your opportunity to make that switch without penalty. The Open Enrollment Period, which runs January 1 through March 31, allows beneficiaries already in Medicare Advantage to switch to a different Advantage plan or return to Original Medicare — but it does not allow switching from Original Medicare into Medicare Advantage.

The disruption to U.S. support for CEPI is one piece of a larger reshaping of American global health engagement that is still unfolding. What is clear is that the infrastructure for pandemic preparedness — the laboratory networks, the vaccine manufacturing relationships, the regulatory coordination — takes years to build and can be damaged quickly. For Medicare beneficiaries, the most actionable response is not to wait and see what happens globally, but to make sure your current coverage is as strong as possible for whatever health challenges the next few years may bring. Review your plan's preventive care benefits, understand your vaccine coverage rules, and use the Annual Enrollment Period to make changes if your current plan falls short.